medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293310; this version posted August 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

pui	potany.	
It is made available under a	CC-BY 4.0 International license	

1	Construction and validation of a predictive model
2	of mortality of tuberculosis-destroyed lung
3	patients requiring mechanical ventilation: A
4	single-center retrospective case-control study
5	
6	Kunping Cui*1,Yi Mao*1,Liangshuang Jiang ² ,Yongli Zheng ² ,Lang Yang ¹ ,Yixiang
7	Yang ¹ ,Guihui Wu ^{#3} ,Shenjie Tang ^{#4}
8	
9	* These two authors contributed equally to the article
10	# These two authors are Corresponding Author
11	¹ Intensive care unit, Public Health Clinical Center of Chengdu, Sichuan, China
12	² Public Health Clinical Center of Chengdu, Sichuan, China
13	³ Tuberculosis department, Public Health Clinical Center of Chengdu, Sichuan, China
14	⁴ Tuberculosis department, Beijing Chest Hostpital capital University, Beijing, China
15	
16	Corresponding Author
17	Guihui Wu
18	E-mail: 3119213561@qq.com
19	shenjie Tang
20	E-mail: tangsj1106@vip.sina.com
21	
22	Background The mortality rate for intensive care unit (ICU) tuberculosis-destroyed lung (TDL)
23	patients requiring mechanical ventilation remains high.
24	Methods We conducted a retrospective analysis of adult TDL patients requiring mechanical
25	ventilation who were admitted to the ICU of a tertiary infectious disease hospital in Chengdu,
26	Sichuan Province, China from January 2019 to March 2023. Univariate and multivariate COX
27	regression analyses were conducted to determine independent patient prognostic risk factors
28	that were used to construct a predictive model of patient mortality.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 **Results** For the 331 study subjects, the median age was 63.0 (50.0-71.0) years, 262 (79.2%) 30 were males and the mortality rate was 48.64% (161/331). Training and validation data sets were 31 obtained from 245 and 86 patients, respectively. Analysis of the training data set revealed that a 32 body mass index (BMI) of $< 18.5 \text{ kg/m}^2$, blood urea nitrogen level of > 7.14 mmol/L and septic 33 shock were independent risk factors for increased mortality of TDL patients requiring mechanical ventilation. These variables were then used to construct a risk-based model for 34 35 predicting patient mortality. Area under the curve, sensitivity and specificity values obtained 36 using the model for the training data set were 0.808, 79.17% and 68.80%, respectively, and 37 corresponding values obtained using the validation data set were 0.876, 95.12% and 62.22%. 38 respectively. Results of concurrent correction curve and decision curve analyses verified the 39 model possessed high predictiveability.

40 **Conclusions** This model may facilitate early identification and classification-based clinical
41 management of TDL patients requiring mechanical ventilation who are at high risk of death.

42 **Key words** tuberculosis-destroyed lung; mechanical ventilation;risk prediction model.

43

44 Tuberculosis(TB) is a chronic infectious disease caused by *Mycobacterium tuberculosis*. In 45 2021, about 10.6 million new TB cases and approximately 1.5 million TB-related deaths, of which 46 90% were caused by pulmonary TB, were reported globally[1]. Importantly, pulmonary TB is 47 associated with a high lung injury rate approaching 68% [2-4], with lung injury leading to 48 development of TB-destroyed lung (TDL) disease in 1.30% of cases[5].TDL is a consequence of 49 improper anti-TB treatment management during the early TB disease stage that causes marked 50 unilateral or bilateral erosion and/or deterioration of lung tissue structure that results in 51 insufficient gas exchange area. As the disease progresses, lung function continues to decline until 52 the normal exchange of inhaled air or oxygen is no longer adequate, resulting in irreversible 53 pulmonary ventilation and ventilation dysfunction [6] that are often accompanied by different 54 degrees of hypoxia, repeated secondary infections, hemoptysis, empyema and 55 pneumothorax.Notably, the TDL patient mortality rate has been reported to be 28%[7-11], while 56 the mortality rate of TDL patients requiring mechanical ventilation (TDL-MV)is much higher 57 (61%)[11]. Therefore, early identification of risk factors affecting TDL-MV patient prognosis and 58 clinical decision-making with regard to implementation of active interventions are of great

59 importance for improving TDL-MV patient prognosis.

60 At present, Acute Physiological and Chronic Health Assessment (APACHE II) and Sequential 61 Organ Failure Assessment(SOFA) scores are often used to assess disease severity of ICU patients 62 with TDL-MV. However, these scoring systems do not provide consistent and accurate mortality 63 risk estimates for patients with specific diseases and thus are of limited value when used for this purpose. For example, although APACHE II scoring has been widely used for conducting clinical 64 65 early prognostic assessments of patients with certain critical diseases, this method requires 66 collection of numerous types of data and thus is complicated, difficult to implement and performs 67 poorly when used within 24 h of ICU admission[12]. SOFA scoringis also of limited value, since 68 this method is mainly used to assess critically ill patients with sepsis or organ dysfunction 69 [13,14]. Meanwhile, it has been reported that APACHE II and SOFA scoring-based methods cannot 70 be used to accurately predict TDL-MV patient mortality rates [15]. Nevertheless, in the face of 71 relentless global TB epidemics, increased clinical awareness of TB pulmonary injury has 72 stimulated research to enhance understanding of its impact on patient outcomes, including a 73 small number of studies based on small numbers of patients exploring risk factors affecting 74 TDL-MV patient prognosis[7,11]. In order to build on the results of those limited studies, here we 75 identified clinical characteristics and independent risk factors related to ICU TDL-MV patient 76 mortality and used them to construct a predictive model. The resulting model should help 77 clinicians achieve early prognosis and improved interventional treatments of TDL-MV patients in 78 order to improve treatment outcomes for this patient population.

79

80 MATERIALS AND METHODS

81 Study design

The study was conducted at the Public Health Clinical Center of Chengdu, a 1,500-bed tertiary hospital specializing in infectious diseases in Chengdu, a city In southwestern China. The Research Ethics Committee of the center approved the study design (approval number:YJ-K2022-02-01) and exempted the study from the informed consent requirement. In this study, 499 prospective TDL patients seeking care at the above mentioned center from January 2019 to March 2023 were screened based on information obtained from the electronic information management system of Chengdu Public Health Clinical Medical Center. Thereafter,

89 study subjects were selected based on study inclusion and exclusion criteria, resulting in 90 enrollment of a total of 331 adult ICU patients with TDL-MV in the study. Of these patients, 245 91 who were admitted to the ICU between January 2019 and March 2022 were assigned to the 92 model training group and the remaining 86 patients who were admitted to the ICU between April 93 2022 and March 2023 were assigned to the model validation group. A flow chart outlining the 94 design of the study is presented in Figure 1. All TDL-MV patients enrolled in the study were 95 diagnosed independently by at least three ICU medical specialists as based on patient 96 epidemiological history, clinical manifestations and auxiliary examination findings (e.g., 97 laboratory, imaging, pathological test results, etc.).TDL patients were diagnosed based 98 onstandard clinical TDL diagnostic criteria as indicated in the guidance document WS288-2017 99 Tuberculosis Diagnosis published in China in 2017, which include the following: chest imaging 100 examinations showing reduced lung tissue volume, secondary bronchiectasis or multiple fibrous 101 thick-wall cavities and calcification, thoracic collapse, traction and displacement of adjacent 102 hilum and mediastinum structures, pleural thickening and adhesion, etc.

103 MV therapeutic indications: (1)Loss of consciousness due to acute respiratory failure; (2) 104 Respiratory rate >35~40 times/min or <6~8 breaths/min, abnormal respiratory rhythm or 105 weak or absent spontaneous respiration; (3)PaO₂< 50mmHg(especially after inhalation of 106 oxygen); (4) Progressive increase of arterial PCO₂level and pH decrease; (5) Respiratory failure 107 after conventional treatmentand/or a trend of worsening respiratory function.

Inclusion criteria: (1)Patients ≥18 years of age, (2)Patients meeting both TDL diagnostic
 criteria and MV therapeutic indications.

Exclusion criteria: (1)Younger than 18 years of age;(1)TDL patients who did not require MV;
(3) Patients with end-stage disease, irreversible disease and patients who could not benefit from
ICU treatment; (4) Patients who died or were discharged within 24 h; (5) Patients with
incomplete clinical data.

114

4



Clinical data and laboratory test results 116

115

To determine risk factors that are associated with TDL-MV patient mortality, the following 117 118 data collected: (1)Patient demographic characteristics, including were 119 gender, age, race, residence, BMI, marriage history, smoking and alcohol consumption history. (2) 120 TB epidemiological characteristics, including bacillus Calmette-Guérin (BCG) vaccination history 121 and history of TB and/or drug-resistant TB infection. (3) Complications, including hemoptysis, 122 pneumothorax and septic shock. (4) Comorbidities, including hypertension, diabetes, chronic liver disease, chronic kidney disease, HIV positive and chronic pulmonary heart disease. (5) 123 124 Critical illness score obtained within 24 h after check-in based on APACHE II or SOFA scoring criteria. (6) Laboratory examination findings obtained within 24 h after check-in that included 125 126 blood levels of white blood cells, red blood cells, hemoglobin, platelets, alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, blood urea nitrogen (BUN), serum 127 creatinine, pH, arterial partial pressure of carbon dioxide(PCO₂), ratio of partial pressure of 128 arterial oxygen to fraction of inspired oxygen(PO₂/FiO₂),lactic acid and levels of CD3+ T cells, 129

130 CD4+ T cells and CD8+ T cells. (7) Findings indicating damaged lung. (8) 30-day prognosis

131 (survival versus non-survival).

132 **Construction and validation of prediction model**

133 Patients who provided model training set data were assigned to survival and non-survival 134 groups according to 30-day prognosis results. In order to identify variables with statistical and 135 clinical significance, patient data were screened via univariate analysis (P < 0.05). Next, potential 136 risk factors affecting TDL-MV patient prognosis were identified using univariate COX regression 137 analysis (P < 0.1)then independent prognostic risk factors were screened using stepwise multivariate COX regression analysis (P < 0.05). Thereafter, the prognostic model of TDL-MV 138 139 patient mortality was generated based on the abovementioned mortality-related independent 140 risk factors and their associated β coefficients.

141 The effectiveness of the model was internally verified using the training data set via three 142 types of analysis: receiver operating characteristic (ROC) curve analysis (prediction model, 143 APACHE II score and SOFA score), calibration curve analysis and decision curve analysis. Next, the 144 validation data set was used to validate the model using the above mentioned analyses then the 145 clinical efficacy of the model for predicting patient mortality was evaluated. Model-based 146 predictions related to TDL-MV patient mortality were next stratified into low-risk and high-risk 147 predictions of mortality according to scores obtained using the training set then Kaplan-Meier 148 survival curves were plotted based on mortality rates obtained from training and validation data 149 sets.

150 Statistical analysis

Data were analyzed using IBM SPSS Statistics 23.0 statistical data analysis software (IBM, Armonk, New York, USA). ROC curve and survival curve analyses were conducted using MedCalc (MedCalc Software, Ltd., Ostend, Belgium). Calibration curves and decision curves were drawn using R software (version 4.5.3,https://CRAN.R-project.org, R Foundation, Vienna, Austria).the calibration curves was plotted used the "rms"package.the decision curve analysis was performed with the "rmda" package.

157 The Kolmogorov-Smirnov test was used for normality testing of continuous variables then 158 normally distributed continuous variables were expressed as the mean ± standard deviation 159 (SD). The independent sample t test was used to conduct comparisons between groups.

160 Non-normally distributed continuous variables were expressed as quartile median values and 161 inter quartile range (IQR) values. Comparisons between groups were conducted using the 162 Mann-Whitney U test. Categorical variables were analyzed using the Chi-square test for 163 continuity correction (χ^2). For univariate Cox regression analysis, variables with P values of<0.1 164 were selected for multivariate Cox regression analysis; those with P values of <0.05 were 165 considered statistically significant. Survival curves were plotted using the Kaplan-Meier method.

166 **Demographic and clinical characteristics of the study population**

167 Ultimately, 331 TDL-MV patients who met all inclusion and exclusion criteria were included in the study, with demographic and clinical characteristics of all subjects shown in Table 1. The 168 169 overall median age of subjects was 63.0(50.0-71.1) years. Study subjects included 262 males (79.2%) and 69 females (20.8%);269 subjects were members of the Han nationality (81.3%) and 170 214 were members of other nationalities (64.7%); 255 were married (77.0%); 203 were smokers 171 172 (61.3%); 127 consumed alcoholic beverages (38.4%);82 (24.8%) previously received the BCG 173 vaccine. Clinically,279 (84.3%) patients were diagnosed with TB based on positive clinical findings, 71 (21.5%) with drug-resistant TB, 22 (6.6%) with hemoptysis, 29 (8.8%) with 174 175 pneumothorax, 107 (32.3%) with chronic pulmonary heart disease, 78 (23.6%) with septic shock and 161 (48.64%) died. 176

Of the 331 TDL-MVpatients, 28 were afflicted with miliary pulmonary TB with extrapulmonary TB involving the central nervous system TB (n=13), tuberculous pericarditis (n=45), TB of the abdominal cavity(n=35) and urinary TB (n= 7).No statistical differences in baseline characteristics were observed between the training set and the validation set except for BCG vaccination history, chronic kidney disease history, chronic pulmonary heart disease and blood lactic acid level (more detailed information is presented in Table 1).

TABLE 1 | Baseline characteristics of the study population.

Variable	Total	Training set	Validation set	statistic	P-valu
	(N=331)	(N=245)	(N=86)	al values	е
Gender				1.579	0.209
Male	262 (79.2)	198 (80.8)	64 (74.4)		
Female	69 (20.8)	47 (19.2)	22 (25.6)		
Age (years)	620 (500710)	620 (480710)	645 (520720)	1 105	0.260
median(IQR)	05.0 (50.0,71.0)	05.0 (40.0,71.0)	04.5 (52.0,75.0)	-1.105	0.209
Race				0.082	0.775

medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293310; this version posted August 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

		-		
lt in mada availabla	under o CC DV	10	International license	
il is illaue avaliable		4.0	international license.	

	2(0, (01, 2))	200(01.()	(0, (00, 2))		
Han nationality	269 (81.3)	200(81.6)	69 (80.2)		
Others	62 (18.7)	45 (18.4)	17 (19.8)	1 0 0 0	0.040
Residence				1.330	0.249
Urban residence	117 (35.3)	91 (37.1)	26 (30.2)		
Rural residence	214 (64.7)	154 (62.9)	60 (69.8)	0.040	0.000
Marriage history				0.940	0.332
Married	255 (77.0)	192 (78.4)	63 (73.3)		
Unmarried	76 (23.0)	53 (21.6)	23 (26.7)		
Smoking					
consumption	203 (61.3)	153 (62.4)	50 (58.1)	0.498	0.480
history					
Alcohol					
consumption	127 (38.4)	97 (39.6)	30 (34.9)	0.597	0.440
history					
BMI (Kg / modian(IOP))	19.0 (18.2,20.3)	19.0 (18.6,20.0)	19.0 (18.0,23.0)	-0.734	0.463
ILmedian(IOR)	17.0 (13.0,21.0)	17.0 (13.0,20.0)	19.0 (14.0,23.0)	-1.556	0.120
SOFA,median(IQR)	3.0 (3.0,5.0)	3.0 (3.0,5.0)	4.0 (3.0,6.0)	-0.321	0.748
BCG vaccination	82(24.8)	52 (216)	20(227)	4 001	0.025
history	02(24.0)	55 (21.0)	29 (33.7)	4.991	0.023
Etiology of				0.262	0.600
tuberculosis				0.263	0.008
+	279 (84.3)	208 (84.9)	71 (82.6)		
-	52 (15.7)	37 (15.1)	15 (17.4)		
History of					
drug-resistant	71 (21.5)	54 (22.0)	17 (19.8)	0.195	0.659
tuberculosis					
History of					
	61 (18.4)	45 (18.4)	16 (18.6)	0.002	0.961
hypertension					
History of diabetes	62 (18.7)	44 (18.0)	18 (18.7)	0.369	0.543
History of chronic		15 ((1)	۲ (۲۵)	0.011	0.010
liver disease	20 (6.0)	15 (6.1)	5 (5.8)	0.011	0.918
History of chronic			- (0.000	0.015
kidney disease	8 (2.4)	3 (1.2)	5 (5.8)	3.906	0.048
HIV positive	5 (1.5)	5 (2.0)	0 (0)	0.674	0.412

Chronic cor	107 (22.2)	02 (29 0)	14 (162)	12 677	0.000
pulmonale	107 (32.3)	93 (30.0)	14 (10.5)	15.077	0.000
hemoptysis	22 (6.6)	16 (6.5)	6 (7.0)	0.020	0.886
pneumothorax	29 (8.8)	20 (8.2)	9 (10.5)	0.422	0.516
Septic shock	78 (23.6)	60 (24.5)	18 (20.9)	0.448	0.503
White blood cells					
$(10^{9}/L)$,median(I	8.47 (6.46,11.64)	8.32 (6.46,11.61)	9.17 (6.65,11.97)	-0.902	0.367
QR)					
Red blood cells	0.04.0.00	2.00.0.07	4.04 - 4.07	1.666	0.000
$(10^{12}/L)$,mean±SD	3.94±0.93	3.89±0.87	4.01±1.06	-1.666	0.098
Hemoglobin				4 (07	0.000
(g/L) ,mean±SD	109.4±24.8	108.0±24.2	113.2±26.1	-1.687	0.093
Platelets	222.2		222.2		
$(10^{9}/L)$,median(I	222.0	220.0 (140.0, 291.0)	222.0	-0.212	0.832
QR)	(141.5,288.0)		(154.0,285.0)		
Alanine					
Aminotransferase					
(U/L) ,median(IQ	20.0 (11.0,38.0)	20.0 (11.0,39.0)	21.0 (12.0,36.0)	-0.155	0.877
R)					
Aspartate					
Aminotransferase					
(U/L),median(IQ	33.0 (21.0,58.5)	34.0 (21.0,59.0)	30.0 (21.0,58.0)	-0.488	0.678
R)					
Total					
Bilirubin(umol/L),	9.9 (6.8,15.4)	10.1 (6.9,15.3)	9.8 (6.8,15.6)	-0.416	0.678
median(IQR)					
Albumin(g/L),medi					
an(IQR)	27.5 (23.8,31.1)	27.4 (23.6,30.9)	28.4 (24.6,31.8)	-1.204	0.228
Blood urea					
nitrogen(mmol/L),	5.46 (3.78,8.24)	5.27 (3.61,8.24)	5.80 (4.40,8.48)	-1.136	0.256
median(IQR)					
Serum					
creatinine(umol/L),	52.5 (43.9,76.7)	51.4 (44.0,76.8)	55.0 (43.3,76.5)	-0.864	0.388
median(IQR)					
pH,median(IOR)	7.42 (7.37,7.47)	7.42 (7.37,7.47)	7.41 (7.37,7.47)	-0.642	0.521
PCO2					
(mmHg),median(I	38.9 (31.8,49.1)	38.6 (31.5,49.2)	39.8 (32.6,49.0)	-0.595	0.552
OR)			,		
PO ₂ /FiO ₂					
(mmHg).median(I	157.3	159.5 (130.0.197.0)	139.6	-1.472	0.141
OR)	(126.0,197.1)		(112.0,202.5)		
Lactic					
acid(mmol/L).medi	2.10 (1.59.2.81)	2.19 (1.65.3.03)	1.81 (1.36.2.38)	-3.428	0.001
an(IOR)	(10,)=01/	(100,000 /		0.120	2.001

CD3+ T cells	226.0		210.0 (205.0		
(cells/ul) ,median	(106 5 528 5)	341.0 (190.0, 541.0)	521.0	-0.062	0.950
(IQR)	(196.5,538.5)		551.07		
CD4+ T cells			107.0		
(cells/ul) ,median	186.0 (84.5,295.5)	179.0 (79.0,286.0)	(105.0.204.0.)	-0.987	0.324
(IQR)			(105.0,504.0)		
CD8+ T cells					
(cells/ul) ,median	121.0 (68.0,216.5)	126.0 (68.0,222.0)	114.0 (69.0,215.0)	0.511	0.609
(IQR)					

184 Note: The continuous variables of normal distribution are expressed as mean ± standard deviation, the non-normal continuous
 185 variables are expressed as median (25th,75th range), and the categorical variables are expressed as number (%).

Abbreviations: BMI. Body Mass Index, APACHE II, Acute Physiology And Chronic Health Evaluation II; SOFA. Sequential Organ
 Failure Assessment.

188

189 Construction of the mortality prediction model

190 Univariate analysis of training set data revealed 13 variables with statistically significant associations with patient mortality rate, including patient age, BMI, septic shock, and blood levels 191 192 of platelets, serum albumin, urea nitrogen, serum creatinine, lactic acid, arterial blood pH, PO_2/FiO_2 and blood levels of CD3+T cells, CD4+ T cells and CD8+T cells (P < 0.05) (Table 2). Of 193 these variables, those significantly associated with greater mortality (P values of <0.1) were 194 195 identified using univariate COX regression analysis(detailed information presented in Table 196 3),including BMI, septic shock,PO₂/FiO₂, levels of serum albumin, BUN and serum creatinine and 197 blood levels of CD8+T cells. Ultimately, variables with P values of <0.5, including BMI, septic shock and BUN (Table 4), were considered independent risk factors for increased TDL-MV patient 198 199 mortality as based on regression β values (Table 5). Variables with β values of <1 received 1 point 200 and those with β values of>1 received 2 points; independent variable scores for each patient were 201 added together to obtain model-based mortality risk prediction scores that the minimum was 0 202 and the maximum was 4 pointes.

`	\sim	2
		-
~	v	J

TABLE 2 Baseline characteristics of the study population in the training set.

Variable	Total (N=245)	Survivors (N=125)	Non-survivors (N=120)	statistic al values	P-valu e
Gender				0.413	0.521
Male	198 (80.8)	103 (82.4)	95 (79.2)		
Female	47 (19.2)	22 (17.6)	25 (20.8)		

Age (years) median(IOR)	63.0 (48.0,71.0)	59.0 (46.0,69.0)	64.0 (51.0,74.5)	-2.227	0.026
Race				0.454	0.501
Han nationality	200 (81.6)	100 (80.0)	100 (83.3)		
Others	45 (18.4)	25 (20.0)	20 (16.7)		
residence				1.372	0.241
Urban residence	91 (37.1)	42 (33.6)	49 (40.8)		
Rural residence	154 (62.9)	83 (66.4)	71 (59.2)		
Marriage history				0.000	0.990
Married	192 (78.4)	98 (78.4)	94 (78.3)		
Unmarried	53 (21.6)	27 (21.6)	26 (21.7)		
Smoking consumption history	153 (62.3)	77 (61.6)	76 (63.3)	0.078	0.779
Alcohol consumption history	97 (39.6)	52 (41.6)	45 (37.5)	0.430	0.512
BMI(kg / m ²),median(IQR)	19.0 (18.6,20.0)	19.3 (18.8,20.0)	18.8 (17.8,19.5)	-4.361	0.000
APACHE II,median(IQR)	17.0 (13.0,20.0)	15.0 (12.0,18.0)	18.5 (15.0,24.0)	-5.318	0.000
SOFA,median(IQR)	3.0 (3.0,5.0)	3.0 (3.0,4.0)	4.0 (3.0,7.0)	-5.707	0.000
BCG vaccination history	53 (21.6)	30 (24.0)	23 (19.2)	0.844	0.358
Etiology of				0.098	0.754
tuberculosis					
+	208 (84.9)	107 (85.6)	101 (84.2)		
-	37 (15.1)	18 (14.4)	19 (15.8)		
History of	54 (22.0)	29 (23.2)	25 (20.8)	0.200	0.655
drug-resistant					
tuberculosis					
History of	45 (18.4)	22 (17.6)	23 (19.2)	0.100	0.752
hypertension					
History of diabetes	44 (18.0)	17 (13.6)	27 (22.5)	3.291	0.070
History of chronic	15 (6.1)	11 (8.8)	4 (3.3)	3.183	0.074

liver disease					
History of chronic	3 (1.2)	0 (0)	3 (2.5)	1.434	0.231
kidney disease					
HIV positive	5 (2.0)	4 (3.2)	1 (0.8)	0.736	0.391
Chronic cor pulmonale	93 (38.0)	51 (40.8)	42 (35.0)	0.875	0.350
hemoptysis	16 (6.5)	9 (7.2)	7 (5.8)	0.187	0.665
pneumothorax	20 (8.2)	12 (9.6)	8 (6.7)	0.703	0.402
Septic shock	60 (24.5)	6 (4.8)	54 (45.0)	53.504	0.000
White blood cells	8.32 (6.46,11.61)	8.40	8.08 (6.51,11.62)	-0.307	0.759
$(10^{9}/L)$,median(IQR)		(6.36,11.44)			
Red blood cells (10 ¹² /L) ,median(IQR)	3.85 (3.37,4.40)	110.0 (95.0,124.0)	104.0 (88.0,121.0)	-1.715	0.086
Hemoglobin (g/L) ,mean±SD	108.0±24.2	110.8±23.6	105.1±24.6	1.844	0.066
Platelets	220.0	238.0 (162.0,307.0)	199.5	-2.536	0.011
$(10^{9}/L)$,median(IQR)	(140.0,291.0)		(112.5,264.0)		
Alanine Aminotransferase (U/L),median(IQR)	20.0 (11.0,39.0)	22.0 (12.0, 39.0)	19.0 (10.0, 40.5)	-0.909	0.363
Aspartate Aminotransferase (U/L),median(IQR)	34.0 (21.0,59.0)	35.0 (22.0,56.0)	32.0 (21.0,59.5)	-0.290	0.772
Total Bilirubin(umol/L) ,me dian(IQR)	10.1 (6.9,15.3)	9.7 (7.1,15.0)	10.3 (6.7,15.7)	-0.330	0.741
Albumin(g/L),median	27.4 (23.6,30.9)	28.10 (24.90,31.80)	26.55	-3.072	0.002
(IQR)			(22.25,29.95)		
Blood urea nitrogen(mmol/L),me dian(IQR)	5.27 (3.61,8.24)	4.49 (3.32,6.40)	6.91 (4.51,9.71)	-4.849	0.000
Serum creatinine(umol/L),m edian(IQR)	51.4 (44.0,76.8)	50.0 (43.0,64.0)	56.8 (45.8,86.0)	-2.982	0.003
pH,median(IQR)	7.42 (7.37,7.47)	7.44 (7.39,7.48)	7.41 (7.35,7.46)	-2.184	0.029
PCO2 (mmHg),median(IQ R)	38.6 (31.5,49.2)	37.9 (31.5,47.3)	39.2 (31.5,53.2)	-0.345	0.730

PO ₂ /FiO ₂	159.5	169.7 (142.0,200.3)	146.2	-3.509	0.000
(mmHg) ,median(IQ					
R)	(130.0,197.0)		(123.3,187.4)		
Lactic	2.19 (1.65,3.03)	2.06 (1.60,2.62)	2.46 (1.70,3.39)	-2.591	0.010
acid(mmol/L) , median					
(IQR)					
CD3+ T cells	341.0	382.0 (209.0,579.0)	294.5	-2.766	0.006
(cells/ul) ,median(IQ					
	(190.0.541.0)		(144.0,467.5)		
R)					
R) CD4+ T cells	179.0	201.0	156.0 (64.5,262.5)	-2.209	0.027
R) CD4+ T cells (cells/ul),median(IQ	179.0	201.0	156.0 (64.5,262.5)	-2.209	0.027
R) CD4+ T cells (cells/ul),median(IQ R)	179.0 (79.0,286.0)	201.0 (102.0,325.0)	156.0 (64.5,262.5)	-2.209	0.027
R) CD4+ T cells (cells/ul),median(IQ R) CD8+ T cells	179.0 (79.0,286.0) 126.0	201.0 (102.0,325.0) 153.0 (77.0.265.0)	156.0 (64.5,262.5) 110.5 (55.0.191.5)	-2.209	0.027
R) CD4+ T cells (cells/ul),median(IQ R) CD8+ T cells (cells/ul),median(IQ	179.0 (79.0,286.0) 126.0	201.0 (102.0,325.0) 153.0 (77.0,265.0)	156.0 (64.5,262.5) 110.5 (55.0,191.5)	-2.209 -2.557	0.027

Note: The continuous variables of normal distribution are expressed as mean ± standard deviation, the non-normal continuous
 variables are expressed as median (25th,75th range), and the categorical variables are expressed as number (%).

Abbreviations: BMI, Body Mass Index, APACHE II, Acute Physiology And Chronic Health Evaluation II; SOFA, Sequential Organ
 Failure Assessment.

208

209 TABLE 3 | Assignment table

factor	Variable name	Assignment specification		
Age	X1	$0=\le 60$ years, $1=>60$ years		
BMI	X2	$0=\ge 18.5$ kg / m ² , $1=\le 18.5$ kg / m ²		
Septic shock	Х3	0=no, 1=yes		
Platelets	X4	0=≥100*10^9/L, 1=<100*10^9/L		
Albumin	X5	0=≥30g/L,1=<30 g/L		
Blood urea nitrogen	X6	0=<7.14mmol/L,1=≥7.14mmol/L		
Serum creatinine	X7	0=≤133umol/L,1=>133umol/L		
Lactic acid	X8	0=≤2.2mmol/L,1=>2.2mmol/L		
pH	X9	0=7.35~7.45,1=<7.35 or>7.45		
PO ₂ /FiO ₂	X10	0=≥200mmHg,1=<200mmHg		
CD3⁺T cells	X11	0=≥770 cells/ul,1=<770 cells/ul		
CD4 ⁺ T cells	X12	0=≥414 cells/ul,1=<414 cells/ul		
CD8⁺T cells	X13	0=≥238 cells/ul,1=<238 cells/ul		
Survival time	Time	30 days of follow-up (days)		
prognosis	Y	0=Survivors, 1=Non-survivors		

210 Abbreviations: BMI, Body Mass Index.

211 TABLE 4 | Univariate and multivariate Cox regression analysis of clinical factors in the training set.

	Univariate analysis		Multivariate analysis		
Variable	HR (95%CI)	Р	β	HR (95%CI)	Р
Age	1.295(0.900~1.861)	0.163			_
BMI	2.931(2.013~4.266)	0.000	0.762	2.144(1.447~3.176)	0.00
Septic shock	4.491(3.105~6.497)	0.000	1.226	3.407(2.309~5.028)	0.00
Platelets	1.328(0.822~2.147)	0.247			
Albumin	1.577(1.043,2.384)	0.031			
Blood urea nitrogen	2.231(1.558~3.195)	0.000	0.682	1.977(1.374~2.845)	0.00
Serum creatinine	3.188(1.850~5.493)	0.000			
Lactic acid	1.338(0.934~1.916)	0.112			
pH	0.954(0.665~1.370)	0.800			
PO ₂ /FiO ₂	1.531(0.964~2.432)	0.071			
CD3⁺T cells	1.471(0.718~3.015)	0.292			
CD4 ⁺ T cells	1.623(0.850~3.102)	0.143			
CD8⁺T cells	1.615(1.008~2.587)	0.046			

215 TABLE 5 | Construction of a risk prediction model for death in patients with TDL-MV

Variable	score
BMI<18.5kg/m ²	1
Septic shock	2
Blood urea nitrogen≥7.14mmol/L	1
Total score	4

216 Abbreviations: BMI, Body Mass Index.

217

212 213 214

218 Validation of the mortality prediction model

Using the training data set to test the risk prediction model revealed an area under the curve (AUC) value for 30-day TDL-MV patient mortality of 0.808, a sensitivity rate of 79.1% and a

specificity rate of 68.80%. Meanwhile, the SOFA score AUC value was 0.702, the sensitivity rate

was 49.17% and the specificity rate was 83.20%, an APACHE II score-based AUC value of 0.696,

sensitivity rate of 50.00% and specificity rate of 77.60% (Figure 2A).

Use of the validation data set to validate the mortality risk prediction model revealed an AUC
value for 30-day TDL-MVpatient mortality of 0.876, a sensitivity rate of 95.12% and a specificity
rate of 62.22%. Meanwhile, the SOFA score-based AUC value was 0.738, the sensitivity rate was
53.66% and the specificity rate was 84.44%, while the APACHE II score-based AUC value was
0.803, the sensitivity rate was 82.93% and the specificity rate was 66.67% (Figure 3A).
Notably, predicted mortality rates obtained using the risk prediction model for both the

training and validation data sets were close to the actual observed TDL-MV patient mortality
rate, thus indicating good calibration curve agreement (Figure 2B, 3B). Moreover, results
obtained via decision curve analysis also showed that the prediction model provided a good net
benefit (Figure 2C, 3C).



medRxiv preprint doi: https://doi.org/10.1101/2023.07.28.23293310; this version posted August 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



259

260

261 **Prognostic comparison and risk stratification**

Failure Assessment; DCA, Decision curve analysis.

Analysis of training data set-derived patient scores generated using the risk prediction model revealed an increase in TDL-MV patient mortality rate with increasing score. With regard to mortality risk, comparisons of patient scores to a critical threshold value resulted in the assignment of 44 patients to the high-risk group (3~7 points) and 201 patients to the low-risk group (0~2 points)(Table 6).An analysis of Kaplan-Meier curves revealed significant differences in survival between high-risk and low-risk patient groups asstratified using the risk prediction model developed usingboth training and validation data sets (Figure2D,3D).

curves of the patients with tuberculosis-destroyed lung requiring mechanical ventilation in validation set. **Abbreviations:** APACHE II, Acute Physiology And Chronic Health Evaluation II; SOFA, Sequential Organ

269

270 **TABLE 6** | Mortality rates of the TDL-MV patients according to the risk prediction model.

	Trainingn set (n=245)		validation set(n=86)			
Score	Survivors (N=125), n	Non-survivors (N=120),n	Mortality (48.98%)	Survivors (N=45),n	Non-survivors (N=41),n	Mortality (47.67%)
0	86	25	22.5	28	2	6.6
1	32	32	50.0	15	17	53.1
2	6	20	76.9	2	5	71.4
3	1	34	97.1	0	10	100
4	0	4	100	0	7	100
≤2	124	77	38.3	45	24	34.7
>2	1	43	97.7	0	17	100

271

272 **DISCUSSION**

273 In this study, we constructed and validated a predictive model of mortality of 274 tuberculosis-destroyed lung patients requiring mechanical ventilation. Internal verification of the 275 risk prediction model indicated good discrimination and prediction performance of the model. 276 thus demonstrating that use of the risk prediction model would not only enable more efficient 277 utilization of limited medical resources, but would also reduce the TDL-MV patient mortality rate. 278 Malnutrition has been shown in numerous studies to be associated with increased TB incidence and severity, anti-TB treatment failure, poorer TB treatment outcomes and increased 279 280 mortality[16-19]. Results obtained in the current study showed that BMI, serum albumin level and blood CD4+ T cell level were significantly reduced in TDL-MV patients, with more 281 282 pronounced reductions observed in the patient group with a high risk of death, BMI is an 283 independent risk factor for TDL-MV patient death, which suggest that ineffective anti-TB treatment of patients with early-stage TB may cause long-term nutritional and immune 284 285 depletionand significantly reduced anti-TB therapeutic responses after disease progression to late-stage TB disease, as consistent with results of previously reported studies of patients with 286

287 severe lung destruction[20-22]. Septic shock is likely induced capillary endothelial injury, tissue 288 microcirculation ischemia and hypoxia. In turn, these effects can lead to vascular paralysis, organ 289 function impairment and severe microcirculatory dysfunction.that can persist even after 290 normalization of hemodynamics has been achieved through fluid resuscitation and 291 administration of vasopressors and anti-infective therapies [23].which is one of several direct 292 causes of ICU patient death and is associated with a mortality rate of about 50% [24-26]. The 293 results of a retrospective nested cohort study reported in 2013 indicated that although clinical 294 manifestations of M.tuberculosis infection-induced septic shock resembled those associated with 295 other bacterial infections, the mortality rate of M.tuberculosis infection-induced septic 296 shock(79.2%)was significantly greater than corresponding rates obtained for all other types of 297 bacterial infections (49.7%)[27]. Indeed, in the current study the mortality rate of ICU TDL-MV 298 patients with septic shock was markedly higher (~92.3%), a result that may reflect the fact that 299 our patients were late-stage TB patients and thus had more severe TB disease than patients in 300 the above mentioned studies. BUN was used to assess renal impairment and protein catabolic 301 function [28-31].A retrospective observational study reported in 2021 involving 845 patients 302 with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).which revealed 303 that the elevated BUN level was associated with increased AECOPD patient mortality[32]. 304 Meanwhile, results of an other retrospective study involving 2682 ICU patients with intracranial 305 hemorrhage indicated that an elevated BUN level was significantly associated with poor 306 prognosis[33]. In addition, results of other studies have confirmed that an elevated BUN level is 307 associated with increased long-term mortality of severely ill patients[34]. Similarly, in our study 308 of TDL-MV patients, the average BUN level of the patient group with greater risk of death exceeded that of the patient group with greater survival. Moreover, an increased BUN level was 309 310 found to be an independent risk factor for increased TDL-MV patient mortality, The underlying 311 mechanism needs further study.

In recent years, the mortality prediction of ICU patients has been widely investigated, but the general ICU severity predictive model were not sufficient for predicting mortality in the population of TDL-MV patients accurately and reliably. In our study, Analysis of risk prediction performance of the model using calibration curve and decision curves generated revealed that the model had excellent prediction ability and predicted patient mortality more accurately than

317 did predictive methods based on traditional APACHE II and SOFA scores. Nevertheless, our study 318 had several limitations. First, it was a single-center, retrospective, observational cohort study 319 based in western China and thus our patient population may not be representative of TDL-MV 320 patients in other regions or countries. Therefore, multi-center, prospective studies of TDL-MV 321 patient prognostic risk factors are needed to externally validate the model. Second, the economic 322 health of western China is relatively poor, especially in rural areas. As a result, some TDL patients 323 resource-poor regions who need mechanical ventilation do not have access to ICUs and thus are 324 under represented in ICU patient populations in such regions, thus leading tobias. Third, the 325 prediction model was constructed using a retrospective design that would inevitably introduce 326 bias into the results to thereby reduce the statistical strength of our conclusions. Fourth, 327 although laboratory data may change as TB progresses, such changes are not adequately 328 captured in retrospective study-based predictive models, since such studies cannot incorporate 329 dynamic changes of indicators in the final analysis.

330

331 CONCLUSION

In this study, a mortality prediction model based on independent risk factors of BMI <</p>
18.5kg/m², septic shock and a BUN level ≥7.14mmol/L was found to have good predictive power
and differentiation ability. Moreover, internal validation of the model using retrospective data of
adult TDL-MV patients admitted to the ICU of Chengdu Public Health Clinical Medical Center
revealed that results obtained using the model were highly stable, reliable and reproducible.
Thus, this model may be clinically useful for achieving early and rapid screening of patients with
TDL who need mechanical ventilation and thus are at high risk of death.

339

340 ACKNOWLEDGMENTS

341 We would like to thank the general practices and patients that participated in follow-up.

342

343 FUNDING

344 This work was supported in part by special funds of Chengdu Science and Technology Bureau

- 345 (2022-YF05-02139-SN), Chengdu Health Commission (2022101) and Sichuan Provincial Science
- and Technology Department (23ZDYF1334).

347

348 AUTHOR CONTRIBUTION

- 349 KC, LJ and YZ received ethical approval for the study. KC, LY and YY participated in patient
- 350 recruitment and data analysis. KC wrote the first draft of the manuscript. All authors reviewed
- and edited the manuscript and approved the final version of the manuscript.
- 352

353 INSTITUTIONAL REVIEW BOARD STATEMENT

- 354 The study was carried out in accordance with the principles of the Declaration of Helsinki. This
- study was approved by the Medical Ethics Committee of Chengdu Public Health Clinical Medical

356 Center (YJ-K2022-02-01).

357

358 INFORMED CONSENT

359 Not applicable.

360

361 DATA AVAILABILITY STATEMENT

- 362 The original contributions presented in the study are included in the article, and further inquiries
- 363 may be directed to the appropriate authors.

364

365 **REFERENCES**

- 366 1.Bagcchi S. WHO's Global Tuberculosis Report 2022. Lancet Microbe. 2023 Jan;4(1):e20. doi:
 367 10.1016/S2666-5247(22)00359-7. Epub 2022 Dec 12. PMID: 36521512.
- 368 2.Han D,Lee H Y,Kim K,et al.Burden and clinical characteristics of high grade tuberculosis destroyed lung: a
- ationwide study[J].Journal of Thoracic Disease, 2019,11(10):4224.
- 370 3.Bongomin F.Post-tuberculosis chronic pulmonary aspergillosis: An emerging public health concern[J].PLoS
- **371** Pathogens,2020,16(8):e1008742.
- 372 4.Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir
- 373 Med. 1989 May;83(3):195-8. doi: 10.1016/s0954-6111(89)80031-9. PMID: 2595036.
- 374 5.Fawibe A E,Salami A K,Oluboyo P O,et al.Profile and outcome of unilateral tuberculous lung destruction in
- 375 Ilorin,Nigeria[J].West African Journal of Medicine,2011,30(2):130-135.
- 376 16.Bobrowitz ID, Rodescu D, Marcus H, Abeles H. The destroyed tuberculous lung. Scand J Respir Dis.

377 1974;55(1):82-8. PMID: 4854707.

- 378 7.Ryu YJ, Lee JH, Chun EM, Chang JH, Shim SS. Clinical outcomes and prognostic factors in patients with
- tuberculous destroyed lung. Int J Tuberc Lung Dis. 2011 Feb;15(2):246-50, i. PMID: 21219689.
- 380 8.Kosif Mısırlıoğlu A, Bayram S, Kıral H, et al. Factors affecting complication rates of pneumonectomy in destroyed
- 381 lung. Turk Gogus Kalp Damar Cerrahisi Derg. 2018 Apr 30;26(2):272-278. doi:
- 382 10.5606/tgkdc.dergisi.2018.14635. PMID: 32082745; PMCID: PMC7024126.
- 383 9.0lgac G, Yilmaz MA, Ortakoylu MG,et al. Decision-making for lung resection in patients with empyema and
- 384 collapsed lung due to tuberculosis. J Thorac Cardiovasc Surg. 2005 Jul;130(1):131-5. doi:
 385 10.1016/j.jtcvs.2004.08.040. PMID: 15999052.
- 386 10.Ruan H, Gong C, Wang J. The Efficacy and Safety of Surgical Treatment for Patients With Tuberculosis Destroyed
- 387 Lung With or Without Chronic Pulmonary Aspergillosis. World J Surg. 2021 May;45(5):1595-1601. doi:
- 388 10.1007/s00268-021-05969-w. Epub 2021 Feb 8. PMID: 33558999; PMCID: PMC8026452.
- 389 11.Park JH, Na JO, Kim EK, et al. The prognosis of respiratory failure in patients with tuberculous destroyed lung.
- **390** Int J Tuberc Lung Dis. 2001 Oct;5(10):963-7. PMID: 11605892.
- 12.Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit
 Care Med. 1985 Oct;13(10):818-29. PMID: 3928249.
- 393 13.Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A
- 394 systematic review. Crit Care. 2008;12(6):R161. doi: 10.1186/cc7160. Epub 2008 Dec 17. PMID: 19091120;
 395 PMCID: PMC2646326.
- 14.Khwannimit B, Bhurayanontachai R, Vattanavanit V. Comparison of the performance of SOFA, qSOFA and SIRS
 for predicting mortality and organ failure among sepsis patients admitted to the intensive care unit in a
 middle-income country. J Crit Care. 2018 Apr;44:156-160. doi: 10.1016/j.jcrc.2017.10.023. Epub 2017 Oct 18.
 PMID: 29127841.
- 400 15.Kim WY, Kim MH, Jo EJ, Eom JS, Mok J, Kim KU, et al. Predicting Mortality in Patients with Tuberculous
 401 Destroyed Lung Receiving Mechanical Ventilation. Tuberc Respir Dis (Seoul). 2018 Jul;81(3):247-255. doi:
 402 10.4046/trd.2017.0126. Epub 2018 Jun 19. PMID: 29926549; PMCID: PMC6030661.
- 403 16. Sinha P, Lönnroth K, Bhargava A, Heysell SK, Sarkar S, Salgame P, Rudgard W, Boccia D, Van Aartsen D,
 404 Hochberg NS. Food for thought: addressing undernutrition to end tuberculosis. Lancet Infect Dis. 2021
 405 Oct;21(10):e318-e325. doi: 10.1016/S1473-3099(20)30792-1. Epub 2021 Mar 27. PMID: 33770535; PMCID:
 406 PMC8458477.
 - 22

- 407 20.Darnton-Hill I, Mandal PP, de Silva A, Bhatia V, Sharma M. Opportunities to prevent and manage undernutrition
- 408 to amplify efforts to end TB. Int J Tuberc Lung Dis. 2022 Jan 1;26(1):6-11. doi: 10.5588/ijtld.21.0488. PMID:

409 34969422; PMCID: PMC8734190.

- 410 18. Koo HK, Min J, Kim HW, Lee J, Kim JS, Park JS, Lee SS. Prediction of treatment failure and compliance in patients
- 411 with tuberculosis. BMC Infect Dis. 2020 Aug 24;20(1):622. doi: 10.1186/s12879-020-05350-7. PMID:
- **412** 32831044; PMCID: PMC7446045.
- 413 19. Horita N, Miyazawa N, Yoshiyama T, Ishigatsubo Y. [Prognosis of patients with tuberculosis]. Kekkaku. 2013
- 414 Jun;88(6):565-70. Japanese. PMID: 23898497.
- 415 20. Peng JC, Zhu YW, Xing SP, Li W, Gao Y, Gong WW. Association of geriatric nutritional risk index with all-cause
- 416 hospital mortality among elderly patients in intensive care unit. Front Nutr. 2023 Mar 23;10:1117054. doi:
- 417 10.3389/fnut.2023.1117054. PMID: 37032766; PMCID: PMC10076778.
- 418 21.Koekkoek KW, van Zanten AR. Nutrition in the critically ill patient. Curr Opin Anaesthesiol. 2017
- 419 Apr;30(2):178-185. doi: 10.1097/ACO.00000000000441. PMID: 28151828.
- 420 22. Li G, Zhou CL, Ba YM, Wang YM, Song B, Cheng XB, Dong QF, Wang LL, You SS. Nutritional risk and therapy for
 421 severe and critical COVID-19 patients: A multicenter retrospective observational study. Clin Nutr. 2021
 422 Apr;40(4):2154-2161. doi: 10.1016/j.clnu.2020.09.040. Epub 2020 Oct 1. PMID: 33077274; PMCID:
- **423** PMC7527833.
- 424 23. Raia L, Zafrani L. Endothelial Activation and Microcirculatory Disorders in Sepsis. Front Med (Lausanne). 2022
- 425 Jun 3;9:907992. doi: 10.3389/fmed.2022.907992. PMID: 35721048; PMCID: PMC9204048.
- 426 24.Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M;
 427 Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic
 428 Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016

429 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289. PMID: 26903336; PMCID: PMC4910392.

- 430 25. Xie J, Wang H, Kang Y, Zhou L, Liu Z, Qin B, Ma X, Cao X, Chen D, Lu W, Yao C, Yu K, Yao X, Shang H, Qiu H, Yang
- 431 Y; CHinese Epidemiological Study of Sepsis (CHESS) Study Investigators. The Epidemiology of Sepsis in Chinese
- 432 ICUs: A National Cross-Sectional Survey. Crit Care Med. 2020 Mar;48(3):e209-e218. doi:
 433 10.1097/CCM.00000000004155. PMID: 31804299.
- 434 26. Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, Ai Y, Xu Y, Liu D, An Y, Wu D, Sun R, Li S, Hu Z, Cao X, Zhou F, Jiang L,
- 435 Lin J, Mao E, Qin T, He Z, Zhou L, Du B; China Critical Care Clinical Trials Group. Epidemiology and outcome of
- severe sepsis and septic shock in intensive care units in mainland China. PLoS One. 2014 Sep 16;9(9):e107181.

437 doi: 10.1371/journal.pone.0107181. PMID: 25226033; PMCID: PMC4167333.

- 438 27.Kethireddy S, Light RB, Mirzanejad Y, Maki D, Arabi Y, Lapinsky S, Simon D, Kumar A, Parrillo JE, Kumar A;
- 439 Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Group. Mycobacterium tuberculosis 440
- septic shock. Chest. 2013 Aug;144(2):474-482. doi: 10.1378/chest.12-1286. PMID: 23429859.
- 441 28.Peng R, Liu K, Li W, Yuan Y, Niu R, Zhou L, Xiao Y, Gao H, Yang H, Zhang C, Zhang X, He M, Wu T. Blood urea 442 nitrogen, blood urea nitrogen to creatinine ratio and incident stroke: The Dongfeng-Tongji cohort. 443 Atherosclerosis. 2021 Sep;333:1-8. doi: 10.1016/j.atherosclerosis.2021.08.011. Epub 2021 Aug 6. PMID:
- 444 34390959.
- 445 29.Baum N, Dichoso CC, Carlton CE. Blood urea nitrogen and serum creatinine. Physiology and interpretations. 446 Urology. 1975 May;5(5):583-8. doi: 10.1016/0090-4295(75)90105-3. PMID: 1093306.
- 447 30.Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karmpaliotis D, Burger AJ, Murphy SA, Cannon 448 CP, Braunwald E, Gibson CM; TIMI Study Group. Serum blood urea nitrogen as an independent marker of 449 subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced 450 glomerular filtration rates. J Am Coll Cardiol. 2005 Jun 7;45(11):1781-6. doi: 10.1016/j.jacc.2005.02.068. 451 PMID: 15936606.
- 452 31.Hong C, Zhu H, Zhou X, Zhai X, Li S, Ma W, Liu K, Shirai K, Sheerah HA, Cao J. Association of Blood Urea Nitrogen 453 with Cardiovascular Diseases and All-Cause Mortality in USA Adults: Results from NHANES 1999-2006. 454 Nutrients. 2023 Jan 16;15(2):461. doi: 10.3390/nu15020461. PMID: 36678332; PMCID: PMC9865447.
- 455 32. Chen L, Zheng H, Wu S, et al. The association of blood urea nitrogen levels upon emergency admission with 456 mortality in acute exacerbation of chronic obstructive pulmonary disease. Chron Respir Dis. 2021 457 Jan-Dec;18:14799731211060051. 10.1177/14799731211060051. doi: PMID: 34806456; PMCID: 458 PMC8743930.
- 459 33. Luo H, Yang X, Chen K, Lan S, Liao G, Xu J. Blood creatinine and urea nitrogen at ICU admission and the risk of 460 in-hospital death and 1-year mortality in patients with intracranial hemorrhage. Front Cardiovasc Med. 2022 461 Nov 10;9:967614. doi: 10.3389/fcvm.2022.967614. PMID: 36440028; PMCID: PMC9685426.
- 462 34. Beier K, Eppanapally S, Bazick HS, Chang D, Mahadevappa K, Gibbons FK, Christopher KB. Elevation of 463 blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of "normal" 464 creatinine. Crit Care Med. 2011 Feb;39(2):305-13. doi: 10.1097/CCM.0b013e3181ffe22a. PMID: 21099426; 465 PMCID: PMC3448784.

24